Molina, JuanNavas, AnaAgüera, María-LuisaRodelo-Haad, CristianAlonso, CoronaRodríguez-Benot, AlbertoAljama, PedroSolana, Rafael2025-01-072025-01-072017-10-311664-3224https://hdl.handle.net/10668/25798The consolidation of single antigen beads (SAB-panIgG) assay in the detection of preformed anti-human leukocyte antigen (HLA) antibodies has improved transplantation success. However, its high sensitivity has limited the allograft allocation for sensitized patients, increasing their waiting time. A modification of the standard SAB-panIgG assay allows the detection of that subset of antibodies capable of binding C1q (SAB-C1q assay). However, the clinical usefulness of SAB-C1q assay for determining the unacceptable mismatches is under discussion. We retrospectively analyzed the impact of preformed donor-specific anti-HLA antibodies (DSA) according to the C1q-binding ability on allograft outcome, examining 389 single-kidney transplanted patients from deceased donors. Recipients with preformed C1q-binding DSA showed the lowest allograft survival up to 7 years (40.7%) compared to patients with preformed non-C1q-binding DSA (73.4%; p = 0.001) and without DSA (79.1%; p enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/C1q-binding antibodiesallograft-loss riskkidney allograft survivalkidney transplantationpreformed anti-HLA antibodiessingle antigen beads assayresearch article29163462open access10.3389/fimmu.2017.01310PMC5671504https://www.frontiersin.org/articles/10.3389/fimmu.2017.01310/pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5671504/pdf